Tag: Novo Nordisk A/S
-
Novo Nordisk’s raised forecast fails to change the debate over its obesity business
Wall Street isn’t convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
-
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
-
Here are the 2 big things we’re watching in the stock market in the week ahead
Four more Club holdings report earnings. Plus, it’s a loaded week of jobs data.
-
Novo Nordisk shares dive after heart medicine fails trial
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
-
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema’s tolerability, after disappointing clinical trial results wiped billions off its market cap.
-
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Shipping and logistics companies are tapping into the growing market of healthcare as cold chain and temperature-controlled facilities become more crucial.
-
Wall Street stumbles as oil surges, and Lilly takes a new path on next-gen obesity drug
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
-
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
-
Jim Cramer says he’s standing by Eli Lilly after rival’s GLP-1 lawsuit. Here’s why
The Investing Club holds its “Morning Meeting” every weekday at 10:20 a.m. ET.
-
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the “deceptive” ads and require the drugmaker to issue corrective advertising.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
